David R Epstein insider trades: AgomAb Therapeutics (AGMB) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
and 3 more companies
Open-market buys and sales
39 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 5, 2026 | AGMB | ↑ Buy | 15,000 | $6.90 | $104K | Direct | Nov 6, 2026 (1d) |
| Nov 2, 2026 | TEM | ↓ Sell | 370 | $74.29 | $27K | Direct | Nov 4, 2026 (2d) |
| Oct 21, 2026 | AGMB | ↑ Buy | 10,000 | $8.88 | $89K | Direct | Oct 22, 2026 (1d) |
| Oct 6, 2026 | AGMB | ↑ Buy | 10,000 | $8.63 | $86K | Direct | Oct 7, 2026 (1d) |
| Sep 1, 2026 | TEM | ↓ Sell | 250 | $65.55 | $16K | Direct | Sep 3, 2026 (2d) |
| Aug 3, 2026 | TEM | ↓ Sell | 370 | $43.40 | $16K | Direct | Aug 5, 2026 (2d) |
| Jun 1, 2026 | TEM | ↓ Sell | 250 | $49.40 | $12K | Direct | Jun 3, 2026 (2d) |
| Mar 2, 2026 | TEM | ↓ Sell | 250 | $50.69 | $13K | Direct | Mar 4, 2026 (2d) |
| Feb 2, 2026 | TEM | ↓ Sell | 370 | $59.41 | $22K | Direct | Feb 4, 2026 (2d) |
| Dec 1, 2025 | TEM | ↓ Sell | 250 | $75.55 | $19K | Direct | Dec 3, 2025 (2d) |
| Nov 3, 2025 | TEM | ↓ Sell | 370 | $90.00 | $33K | Direct | Nov 5, 2025 (2d) |
| Sep 2, 2025 | TEM | ↓ Sell | 250 | $73.64 | $18K | Direct | Sep 4, 2025 (2d) |
| Aug 1, 2025 | TEM | ↓ Sell | 370 | $55.16 | $20K | Direct | Aug 5, 2025 (4d) |
| Jun 2, 2025 | TEM | ↓ Sell | 250 | $55.20 | $14K | Direct | Jun 4, 2025 (2d) |
| May 1, 2025 | TEM | ↓ Sell | 370 | $53.50 | $20K | Direct | May 5, 2025 (4d) |
| Mar 17, 2025 | TEM | ↓ Sell | 990 | $46.83 | $46K | Direct | Mar 19, 2025 (2d) |
| Mar 3, 2025 | TEM | ↓ Sell | 250 | $57.52 | $14K | Direct | Mar 5, 2025 (2d) |
| Feb 3, 2025 | TEM | ↓ Sell | 370 | $53.31 | $20K | Direct | Feb 5, 2025 (2d) |
| Dec 11, 2024 | TEM | ↓ Sell | 620 | $41.81 | $26K | Direct | Dec 13, 2024 (2d) |
| Nov 10, 2023 | SGEN | ↓ Sell | 10,620 | $213.01 | $2.3M | Direct | Nov 13, 2023 (3d) |
| May 27, 2022 | EVLO | ↑ Buy | 17,123 | $1.46 | $25K | Direct | May 31, 2022 (4d) |
| Apr 21, 2022 | RUBY | ↑ Buy | 30,000 | $1.44 | $43K | Direct | Apr 22, 2022 (1d) |
| Mar 16, 2022 | AXLA | ↑ Buy | 26,178 | $1.91 | $50K | Direct | Mar 18, 2022 (2d) |
| Feb 11, 2021 | RUBY | ↓ Sell | 26,704 | $14.93 | $399K | Direct | Feb 16, 2021 (5d) |
| Feb 10, 2021 | RUBY | ↓ Sell | 98,737 | $14.88 | $1.5M | Direct | Feb 10, 2021 (0d) |
| Dec 11, 2020 | EVLO | ↑ Buy | 7,700 | $6.66 | $51K | Direct | Dec 14, 2020 (3d) |
| Aug 31, 2020 | EVLO | ↑ Buy | 10,000 | $4.44 | $44K | Direct | Sep 1, 2020 (1d) |
| May 18, 2020 | AXLA | ↑ Buy | 50,000 | $4.75 | $238K | Direct | May 20, 2020 (2d) |
| Mar 17, 2020 | RUBY | ↑ Buy | 5,000 | $3.76 | $19K | Direct | Mar 19, 2020 (2d) |
| Mar 13, 2020 | RUBY | ↑ Buy | 10,000 | $3.91 | $39K | Direct | Mar 17, 2020 (4d) |
| Feb 28, 2020 | AXLA | ↑ Buy | 14,805 | $3.66 | $54K | Direct | Mar 2, 2020 (3d) |
| Nov 27, 2019 | AXLA | ↑ Buy | 15,005 | $3.57 | $54K | Direct | Dec 3, 2019 (6d) |
| Nov 27, 2019 | AXLA | ↑ Buy | 15,005 | $3.57 | $54K | Direct | Dec 2, 2019 (5d) |
| Aug 2, 2019 | AXLA | ↑ Buy | 6,941 | $7.00 | $49K | Direct | Aug 5, 2019 (3d) |
| Jul 17, 2019 | AXLA | ↑ Buy | 1,000 | $7.55 | $8K | Direct | Jul 18, 2019 (1d) |
| Jul 10, 2019 | AXLA | ↑ Buy | 5,796 | $8.24 | $48K | Direct | Jul 10, 2019 (0d) |
| Jul 3, 2019 | AXLA | ↑ Buy | 4,556 | $8.76 | $40K | Direct | Jul 3, 2019 (0d) |
| Jun 28, 2019 | AXLA | ↑ Buy | 5,500 | $10.02 | $55K | Direct | Jul 1, 2019 (3d) |
| Jun 26, 2019 | AXLA | ↑ Buy | 14,500 | $9.57 | $139K | Direct | Jun 27, 2019 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other AGMB insiders
Open-market trades in the last 12 months
About David R Epstein's insider trades
David R Epstein is a director at AgomAb Therapeutics (AGMB). Since Jun 26, 2019, David has reported 20 open-market purchases worth $1.3M and 19 sales worth $4.5M on SEC Form 4. In the last 12 months: 3 buys ($279K) and 7 sales ($126K).
Their filings also include grants and awards (39 filings), option exercises (24 filings), shares returned to the company (6 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every AGMB insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.